Saturday, 24 October 2026

The week in review

The close-of-day market read is neutral, unchanged from the prior read, because the S&P 500 is comfortably above its long-term trend but participation is too thin to call risk-on. The SPDR S&P 500 ETF (SPY) closed at 759.83, 3.8% above its 200-day exponential moving average (EMA) of 731.96. Breadth is mixed: 519 of 978 names sit above their own 50-day EMA, or 53.1%. The Cboe Volatility Index (VIX) stood at 19.03 at the 22 October 2026 close, an elevated reading.

The call has a fixed rule set. No risk-off trigger is met, and a risk-on read needs breadth above 60% (now 53.1%). The read turns risk-off if SPY closes more than 2% below its 200-day EMA (now +3.8%), if breadth falls under 40% (now 53.1%), or if VIX rises above 28 (now 19.03).

Rates moved more than anything else this week. Federal Reserve data show the 10-year Treasury yield at 4.96% on 22 October 2026, down 13 basis points week over week. The 2-year yield fell 9 basis points to 4.65%. The 10-year minus 2-year spread was 0.31% on 23 October 2026, down 4 basis points. Breakeven inflation barely moved, at 2.34%, down 1 basis point. The real 10-year rate fell 12 basis points to 2.62%.

The drop in yields came from real rates, not inflation expectations. This suggests bond markets priced slower growth or easier policy rather than hotter prices. That reading fails if breakeven inflation, rather than the real rate, carries the next large move in the 10-year yield.

Credit and labor point in different directions. The high-yield credit spread widened 9 basis points to 3.40% on 22 October 2026. Initial jobless claims fell 6K to 194K for the week ending 17 October 2026. Unemployment was 4.2% and the federal funds rate 3.75% at the September reading. These are context for the read. They do not move the call.

Themes in motion

Two narratives are gaining strength, five are maturing, and three are saturated. The mergers and acquisitions and special situations theme is accelerating. The travel and leisure theme is accelerating as well.

The maturing group is broad. Consumer discretionary rotation, AI enterprise software, medtech and diagnostics, managed care and health services, and fintech and consumer credit are all maturing. Each story is established and now depends on fresh confirmation from results.

Three narratives are saturated. Precision biotech and therapeutics is saturated, as are emerging markets and oil, energy and geopolitics. Two of these meet hard tests within a day: medical-meeting data for biotech and Brazil's presidential runoff for emerging markets. A saturated theme has less room for a positive surprise to change how it is valued.

Under the lens

The names under the closest lens this week are those whose stories face a dated test within days. They fall into two groups: Brazil-exposed companies ahead of the presidential runoff, and drug and diagnostics developers presenting clinical data. The research refreshed 569 dossiers this week.

• Brazil runoff group: Inter & Co. (INTR), Itaú Unibanco (ITUB), PagSeguro Digital (PAGS), Petrobras (PBR). These four share one event: the 25 October runoff between Flávio Bolsonaro and Luiz Inácio Lula da Silva. Grouping them means a single political result can move a bank, a digital lender, a payments firm and a state-linked oil producer together. The vote settles the policy question for all four at once.
• Oncology data at the European Society for Medical Oncology (ESMO) congress: Moderna (MRNA), Inhibrx Biosciences (INBX), Agenus (AGEN), Immuneering (IMRX). Moderna presents the full INTerpath-001 results in the Presidential Symposium on 24 October. Inhibrx gives an oral presentation of the HexAgon-HN Phase 2 primary analysis on 25 October. Agenus presents the NEOASIS poster on pre-surgery treatment in dMMR colorectal cancer. Immuneering presents a trial-in-progress poster for MAPKeeper 301. Full data presentations settle questions about effect size and durability; a trial-design poster does not.
• GRAIL (GRAL). The company presents an ESMO poster on 25 October on diagnostic workups after a positive Galleri cancer-screening test in clinical practice. Real-world follow-up data bear on how the test performs outside trials, which sits within the medtech and diagnostics theme.
• Kidney disease readouts: Climb Bio (CLYM), Maze Therapeutics (MAZE). Climb Bio presents preliminary Phase 2 PrisMN data for budoprutug in primary membranous nephropathy on 24 October. Maze presents updated Phase 2 HORIZON data for MZE829 the same day, 5:40–5:50 PM Mountain Time. Climb's preliminary data can set early expectations for the program; Maze's update shows whether earlier results held.

The week ahead

Next week's catalysts are concentrated in the 24 October–25 weekend, before markets reopen. Each one resolves a single named question for its company or theme.

• 24 October, Moderna (MRNA): The full INTerpath-001 presentation and company webcast confirm or weaken the headline result, depending on the detailed efficacy and safety figures.
• 24 October, Climb Bio (CLYM): The preliminary Phase 2 PrisMN data are the first clinical read on budoprutug in primary membranous nephropathy.
• 24 October, Maze Therapeutics (MAZE): The updated HORIZON data for MZE829 confirm earlier Phase 2 results if the effect holds with more follow-up, and break them if it fades.
• 24 October, iQIYI (IQ): The season 2 premiere of "The Blooming Journey" tests whether a returning title draws viewers to the platform.
• 25 October, Brazil runoff (INTR, ITUB, PAGS, PBR): The result settles the policy outlook for Brazilian banks, payments firms and Petrobras, and tests the saturated Emerging markets theme.
• 25 October, Inhibrx Biosciences (INBX): The HexAgon-HN primary analysis is the pivotal Phase 2 read for the program in head and neck cancer.
• 25 October, Agenus (AGEN), GRAIL (GRAL), Immuneering (IMRX): ESMO posters add data on pre-surgery immunotherapy in colorectal cancer, on Galleri in routine practice, and on the MAPKeeper 301 trial design.
• 25 October, Anavex Life Sciences (AVXL): The NORD Rare Diseases and Orphan Products Breakthrough Summit begins.
• 24 October–25, SpaceX (SPCX) and Nuvalent (NUVL): Both have dated events on the calendar, with no published description.

Beyond the weekend, the regime read stands on the same three conditions each session. It turns risk-off if SPY closes more than 2% below its 200-day EMA (now +3.8%), if breadth falls under 40% (now 53.1%), or if VIX rises above 28 (now 19.03). A risk-on read needs breadth above 60% (now 53.1%).